Onkure Therapeutics Inc. has described phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities, scoliosis and PIK3CA related overgrowth spectrum (PROS), among others.
Biogen Inc. has divulged 3-β-hydroxysteroid-δ(8),δ(7)-isomerase (EBP) inhibitors reported to be useful for the treatment of autoimmune disease and multiple sclerosis.
Selene Therapeutics Ltd. has identified brain permeable dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of epilepsy, cancer, Alzheimer’s disease, rheumatoid arthritis and multiple sclerosis.
Scientists at Charles University and Mayo Foundation for Medical Education and Research (MFMER) have synthesized DNA topoisomerase II β inhibitors reported to be useful for the treatment of cardiotoxicity.
The Scripps Research Institute has disclosed κ-opioid receptor antagonists reported to be useful for the treatment of depression, anxiety, schizophrenia, obesity, migraine, substance abuse and dependence, epilepsy and eating disorders, among others.
Selenoprotein O (SELENOO) is an antioxidant mitochondrial enzyme that transfers AMP from ATP to protein substrates in a post-translational process known as AMPylation.
Mood disorders include major depressive disorder and bipolar disorder, and they affect mood and cognition. It is known that mood disorders share a genetic heritable background, but the environmental factors also play a key role here. Recent data had highlighted the potential role of micro RNAs (miRNAs) in the pathogenesis of mood disorders.
Myrobalan Therapeutics Inc. has been awarded a grant of over $850,000 from the National Multiple Sclerosis Society to support the preclinical and translational development of MRO-002, a G-protein-coupled receptor 17 (GPR17) antagonist, for the treatment of progressive multiple sclerosis (MS).
Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology to develop two bispecific antibody-drug conjugate (ADC) programs for solid tumors.
APG-777 is an anti-IL-13 humanized monoclonal antibody (mAb) designed to block Th2 inflammatory signaling mediated by the IL-13Rα1/IL-4Rα complex, while APG-990 is a fully human anti-OX40L mAb that that blocks type 1/2/3 inflammatory signaling. Apogee Therapeutics Inc. is studying the combination effects of APG-777 and APG-990 as potential therapy for atopic dermatitis (AD).
RSS
